<DOC>
	<DOCNO>NCT01865279</DOCNO>
	<brief_summary>This trial conduct Europe . The aim trial investigate safety , tolerability , pharmacokinetics ( exposure trial drug body ) pharmacodynamics ( effect investigate drug body ) insulin degludec ( insulin 454 ) , explorative formulation , similar propose commerical formulation .</brief_summary>
	<brief_title>Safety , Tolerability , Pharmacokinetics Pharmacodynamics Explorative Formulation Insulin Degludec</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Isophane insulin , beef</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<mesh_term>Isophane Insulin , Human</mesh_term>
	<mesh_term>Insulin , Isophane</mesh_term>
	<criteria>HEALTHY SUBJECTS : Subjects healthy male subject , consider generally healthy base assessment medical history , physical examination clinical laboratory data , judge Investigator Body mass index ( BMI ) 18.027.0 kg/m^2 ( inclusive ) SUBJECTS WITH TYPE 1 AND TYPE 2 DIABETES : Subjects male volunteer , consider generally healthy , except underlie diabetes mellitus , base assessment medical history , physical examination clinical laboratory data , judge Investigator Diagnosed type 1 diabetes mellitus treat insulin least 12 month diagnose type 2 diabetes mellitus least 12 month Body Mass Index ( BMI ) 18.027.0 kg/m^2 ( inclusive ) subject type 1 diabetes 25.035.0 kg/m^2 ( inclusive ) subject type 2 diabetes Glycogylated haemoglobin ( HbA1c ) maximum 8.5 % base central laboratory result Subjects type 2 diabetes must treat insulin past 3 month prior screen Participation trial involve investigational product within 3 month precede start dose History significant multiple drug allergy know allergy trial product medicine chemically related trial product , judge investigator Hepatitis carrier Hepatitis B surface antigen ( HBsAg ) Hepatitis C antibody positive result test human immunodeficiency ( HIV ) antibodies Any clinically significant abnormal haematology biochemistry screen test , judge investigator Subjects donate blood plasma past month excess 1000 ml within 12 week precede screen</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>